probabl
nrti
molecul
viz
n
dideoxythymidin
ocarboxyl
ester
prodrug
synthes
screen
hiv
vesicular
stomat
sever
virus
compound
show
good
antivir
activ
ec
valu
mm
si
vsv
hela
hel
cell
line
howev
lead
compound
deriv
show
remark
activ
virus
molecular
dock
studi
rt
use
ds
pymol
softwar
shown
mark
differ
interact
pattern
lead
compound
azt
revers
transcriptas
rt
primari
target
develop
antihiv
drug
enzym
respons
gener
linear
dsdna
ssrna
e
genet
materi
dsdna
act
proviru
lead
viral
express
integr
host
genom
transcript
translat
process
sever
drug
inhibit
rt
classifi
nucleo
ide
rt
inhibitor
n
rti
nonnucleosid
rt
inhibitor
nnrti
nrti
emerg
import
therapeut
agent
develop
antihiv
drug
nrti
intracellular
phosphoryl
activ
triphosph
form
cellular
kinas
act
competit
inhibitor
respect
dntp
substrat
molecul
incorpor
rt
grow
templateprim
caus
chain
termin
sinc
lack
oh
group
necessari
chain
elong
thu
inhibit
rt
despit
tremend
util
nucleosid
analogu
may
caus
seriou
cellular
toxic
interact
human
dna
polymeras
g
present
mitochondria
result
mitochondri
dysfunct
thu
nrti
show
mani
side
effect
addit
four
signific
obstacl
current
limit
clinic
applic
nucleosid
analogu
oral
absorpt
cellular
uptak
short
halflif
viral
resist
need
new
nucleosid
mimic
prodrug
overcom
limit
alreadi
report
sever
nucleosid
nonnucleosid
molecul
signific
antivir
activ
nrti
virtu
act
chain
termin
strand
dna
synthesi
revers
transcript
develop
potenti
drug
hivaid
order
explor
new
inhibitor
report
synthesi
n
dideoxythymidin
dmat
oester
prodrug
amino
fatti
acid
lead
molecul
dmat
design
keep
azt
approv
nrti
drug
hivaid
mind
azido
group
replac
dimethylamino
function
fig
thu
molecul
dideoxynucleosid
expect
act
nrti
rt
enzym
similarli
prodrug
biodegrad
ester
linkag
suppos
enhanc
cellular
uptak
due
high
lipophil
natur
molecul
evalu
activ
variou
virus
like
vesicular
stomat
reoviru
parainfluenza
viru
mani
other
q
work
present
nucleic
acid
symposium
seri
held
japan
ref
new
thymidin
analogu
viz
n
synthes
thymidin
shown
scheme
dimethoxytrityl
mesylthymidin
obtain
oh
select
protect
dmtcl
follow
mesyl
mscl
react
potassium
phthalimid
wit
introduct
nucleophil
phthalimid
ion
sugar
moieti
convers
elimin
mesyloxi
group
effect
intramolecular
displac
attack
carbonyl
group
thymidin
result
format
anhydronucleosid
intermedi
result
well
accord
literatur
data
suggest
condit
phthalimid
ion
introduc
ribo
configur
phthalimid
deriv
treat
methanol
methylamin
methanolysi
aminolysi
result
format
compound
reaction
formic
acid
aqueou
formaldehyd
yield
reaction
formaldehyd
use
sourc
methyl
group
formic
acid
suppli
hydrogen
involv
reduct
treatment
also
remov
dmt
group
compound
expect
uv
absorpt
spectra
intermedi
similar
thymidin
dissimilar
r
f
valu
show
chang
took
place
sugar
moieti
aglycon
part
compound
screen
antivir
potenti
hiv
sever
virus
result
shown
tabl
lead
compound
dmat
prodrug
found
inact
rod
iiib
strain
show
toxic
compound
show
similar
valu
cc
ec
virus
studi
thu
activ
observ
lphenylalanyl
deriv
free
amino
function
potenti
activ
ec
mm
vsv
hela
hel
cell
cultur
ec
valu
compound
found
eightfold
lower
cc
valu
si
besid
also
show
moder
activ
ec
around
mm
coxsacki
rsv
hela
cell
cultur
ec
valu
found
activ
vv
tk
hsv
hel
cell
line
sv
ptv
vero
cell
cultur
ecv
fipv
fhv
crfk
cell
cultur
decanoyl
deriv
shown
activ
fcv
fipv
fhv
crfk
cell
cultur
compound
also
test
influenza
subtyp
influenza
b
mdck
cell
line
howev
none
compound
abl
inhibit
cytopath
effect
influenza
b
viru
subtox
concentr
highest
concentr
test
observ
compound
show
antivir
properti
vsv
ec
fcv
ec
respect
howev
antivir
potenc
prodrug
still
significantli
lower
establish
antivir
drug
e
dhpa
bvdu
ribavirin
vsv
evid
cc
ec
valu
shown
tabl
sinc
nucleosid
exhibit
modest
bioavail
prepar
prodrug
molecul
use
amino
fatti
acid
improv
bioavail
chemic
stabil
done
ensur
enhanc
cellular
uptak
sustain
releas
drug
molecul
without
compromis
properti
lead
compound
prodrug
show
antivir
activ
wherea
prodrug
show
activ
albeit
littl
fcv
fhv
howev
prodrug
show
good
activ
vsv
si
valu
equal
enhanc
reactiv
free
amino
acid
ester
prodrug
may
attribut
electron
activ
posit
charg
amino
terminu
physiolog
ph
deriv
support
fact
lamino
acid
ester
enhanc
nucleosid
absorpt
via
human
peptid
transport
activ
transport
system
furthermor
sinc
bone
marrow
progenitor
cell
lack
activ
transport
system
amino
acid
prodrug
expect
show
reduc
toxic
bone
marrow
level
therefor
compound
potenti
develop
effect
antivir
agent
vsv
lead
compound
dideoxynucleosid
expect
act
chain
termin
thu
interfer
viral
cell
metabol
prodrug
design
synthes
enhanc
cellular
uptak
howev
molecul
show
almost
antihiv
activ
rather
prove
cytotox
might
dmat
r
tyrosynyl
lysinyl
phenylalanyl
valyl
etc
r
decanoyl
myristoyl
pamitoyl
etc
expect
introduct
dimethylamino
group
c
ribos
moieti
show
interact
hiv
rt
molecular
dock
experi
lead
molecul
design
similar
azt
complet
fail
fulfil
object
surpris
see
replac
azido
group
dimethylamino
group
turn
molecul
highli
toxic
fact
lead
molecul
dmat
prodrug
dideoxynucleosid
structur
featur
similar
azt
show
activ
hiv
rather
prove
toxic
prompt
us
studi
interact
rt
perform
elabor
molecular
comput
studi
use
softwar
discoveri
studio
ds
molecul
show
strike
differ
azt
e
approv
antihiv
drug
shown
tabl
physiochem
studi
suggest
molecul
e
azt
dmat
follow
lipinski
rule
five
mark
differ
molecular
volum
total
polar
surfac
area
tpsa
log
p
valu
similarli
dock
experi
also
show
quit
differ
pattern
interact
rt
fig
although
dmat
form
one
hbond
rt
azt
crucial
interact
shown
azt
miss
case
dmat
azido
function
azt
form
three
hbond
e
one
two
amino
acid
constitut
dntpbind
site
wherea
dimethylamino
function
dmat
form
hbond
similarli
hbond
form
phosphat
moieti
azt
ttp
well
miss
case
dmat
howev
aglycan
part
molecul
form
two
hbond
oxo
group
atom
sugar
ring
stabil
dmattpert
complex
also
less
azttpert
ttpert
complex
evid
minim
energi
compar
account
interact
ttp
azttp
dmattp
stabil
respect
complex
rt
shown
tabl
thu
physiochem
dock
studi
suggest
possibl
reason
inact
lead
molecul
prodrug
conclus
synthes
n
dideoxythymidin
ocarboxyl
ester
prodrug
deriv
evalu
antivir
activ
iii
b
rod
strain
vesicular
stomat
viru
mani
other
observ
compound
show
moder
antivir
properti
vsv
ec
fcv
ec
respect
mechanist
studi
molecul
progress
vesicular
stomat
felin
corona
felin
herp
virus
infer
drawn
present
studi
nucleosid
analogu
effect
nrti
dideoxi
deriv
suffici
enough
criterion
rather
must
possess
characterist
featur
requisit
interact
dntpbind
site
rt
enzym
shall
definit
help
design
new
nrti
molecul
chemic
obtain
e
merck
india
ltd
india
sigmaealdrich
chemic
compani
usa
melt
point
determin
electrotherm
apparatu
uncorrect
silica
gel
tlc
column
chromatographi
mesh
obtain
e
merck
india
ltd
uv
measur
carri
hitachi
spectrophotomet
hplc
analys
perform
use
mm
column
solvent
system
meoh
h
flow
rate
mlmin
ad
binari
gradient
shimadzu
hplc
system
h
nmr
spectra
record
drx
mhz
instrument
use
dmsod
solvent
tm
intern
standard
c
nmr
spectra
record
cdcl
varian
spectromet
oper
mhz
mass
spectra
obtain
use
thermofinnigan
tracedsq
electrospray
ioniz
esi
mass
spectromet
element
analys
carri
perkineelm
analyz
solvent
dri
distil
prior
use
thymidin
g
mmol
suspend
dri
pyridin
ml
ml
round
bottom
flask
ad
dmap
mg
equival
tea
ml
equival
dmtcl
g
equival
stir
reaction
mixtur
h
tlc
point
show
complet
disappear
thymidin
content
cool
c
methanesulfonyl
chlorid
ml
mmol
ad
dropwis
stir
continu
h
reaction
mixtur
allow
warm
c
stir
reaction
mixtur
addit
min
content
pour
crush
icewat
viscou
mass
obtain
extract
chloroform
ml
wash
water
ml
organ
phase
dri
anhydr
sodium
sulfat
filter
evapor
rotari
evapor
obtain
crude
product
silica
gel
column
purif
linear
gradient
ethyl
acet
hexan
afford
pure
compound
dimethoxytrityl
dideoxythymidin
reflux
h
potassium
phthalimid
g
dimethylformamid
ml
solvent
remov
reduc
pressur
residu
extract
ethyl
acet
ethyl
acet
layer
final
wash
water
ml
dri
anhydr
na
concentr
get
titl
compound
crude
form
g
compound
g
stir
methylamin
ml
methanol
c
h
reaction
mixtur
evapor
oili
residu
wash
water
dissolv
ethanol
ml
treat
hydrochlor
acid
neutral
residu
methylamin
acid
solut
concentr
reduc
pressur
result
crystal
crystal
separ
residu
water
acid
remov
coevapor
benzen
reduc
pressur
mother
liquor
subject
crystal
crystallin
residu
tritur
ethanol
ether
titl
compound
obtain
colorless
crystal
g
dicyclohexylcarbodiimid
mg
mmol
ad
stir
solut
consist
n
mg
mmol
dmap
mg
mmol
natboclphenylalanin
mg
mmol
pyridin
ml
anhydr
condit
progress
reaction
monitor
tlc
reaction
complet
h
separ
dcu
filter
filtrat
evapor
dryness
reduc
pressur
titl
compound
purifi
column
chromatographi
silica
gel
use
mixtur
ethyl
acetatehexan
eluent
yield
mg
mp
c
r
f
dcm
meoh
uv
etoac
l
max
nm
hplc
nm
r
min
h
nmr
dmsod
decanoyl
chlorid
ml
mmol
ad
dropwis
icecold
stir
solut
consist
lead
compound
mg
mmol
dmap
g
mmol
pyridin
ml
reaction
mixtur
stir
overnight
room
temperatur
anhydr
condit
reaction
mixtur
concentr
reduc
pressur
partit
ethyl
acet
water
organ
fraction
concentr
residu
product
purifi
column
chromatographi
silica
gel
use
ethyl
acetatehexan
eluent
yield
mg
mp
c
nh
thi
cell
cultur
prepar
microtit
tray
inocul
correspond
viru
stock
dilut
prove
infect
cell
cultur
h
viru
adsorpt
cell
c
residu
viru
replac
cell
cultur
medium
eagl
minimum
essenti
medium
supplement
fetal
calf
serum
variou
concentr
test
compound
viru
cytopathogen
record
reach
complet
untreat
virusinfect
cell
cultur
e
day
vesicular
stomat
viru
day
coxsacki
day
vaccinia
herp
simplex
type
sindbi
day
respiratori
syncyti
viru
day
reo
parainfluenza
virus
antivir
activ
compound
express
ec
concentr
mm
requir
inhibit
virusinduc
cytopathogen
cytotox
compound
assess
basi
two
paramet
alter
normal
cell
morpholog
ii
inhibit
macromolecul
dna
rna
protein
synthesi
cytotox
cc
compound
examin
trypan
blue
exclus
test
evalu
cytotox
uninfect
confluent
cell
cultur
treat
variou
concentr
test
compound
incub
parallel
virusinfect
cell
cultur
prepar
plastic
tray
contain
well
mm
diamet
falcon
plastic
day
incub
c
co
incub
cell
cultur
confluent
cultur
medium
remov
well
ml
mainten
medium
contain
serial
concentr
test
compound
ad
cell
control
ml
mainten
medium
without
compound
ad
cultur
incub
c
day
incub
compound
withdrawn
viabil
cell
determin
trypan
blue
exclus
method
antivir
screen
iiib
rod
strain
monitor
effici
test
compound
inhibit
syncytia
format
hiv
infect
cell
follow
mtt
method
molecular
dock
compound
prodrug
dntpbind
site
rt
carri
use
ds
softwar
pdb
code
rt
cdocker
use
flexibl
dock
done
stimul
anneal
done
get
energyminim
structur
molecul
energyminim
form
dock
rt
visual
done
use
pymol
softwar
molecular
model
studi
perform
intel
pentium
ghz
processor
gb
ram
window
xp
profession
version
oper
system
